The Warburg Effect: A Century-Old Discovery That Still Shapes How We Think About Cancer

Yoon Hang Kim MD MPH Board Certified, Preventive Medicine Practice of Yoon Hang Kim MD | www.directintegrativecare.com

In 1924, a German biochemist named Otto Warburg made an observation about cancer cells that puzzled his contemporaries, was largely ignored for decades, and has now become one of the most important concepts in modern oncology. One hundred years later, his finding — that cancer cells metabolize glucose differently from normal cells — underpins how we diagnose cancer, how we understand its biology, and how several integrative oncology interventions may exert their effects.

This post explains what Warburg actually found, what he got right, what he got wrong, and why it matters for patients and clinicians navigating the landscape of cancer care in 2026.

What Warburg Actually Discovered

In the early 1920s, Otto Warburg was working at the Kaiser Wilhelm Institute in Berlin, studying how cells use oxygen. Using thin slices of tumor tissue and an instrument called a manometer, he measured two things simultaneously: how much oxygen the tissue consumed (respiration) and how much lactate it produced (fermentation).

Normal cells, when oxygen is available, send glucose through a metabolic pathway called oxidative phosphorylation — a highly efficient process that occurs in the mitochondria and produces approximately 36 molecules of ATP (the cell's energy currency) per molecule of glucose. When oxygen is scarce, cells fall back on glycolysis — an older, less efficient pathway that converts glucose to lactate and produces only 2 ATP per glucose. This is the same process that makes your muscles burn during intense exercise.

Warburg's surprising finding: cancer cells were performing glycolysis at enormously high rates — up to 200 times that of normal tissue — even when oxygen was abundantly available. The cancer cells were choosing the inefficient pathway despite having access to the efficient one. He published these findings in 1924, and they were later summarized in his landmark 1956 paper "On the Origin of Cancer Cells" in Science.

This phenomenon — glycolysis in the presence of oxygen — was eventually named "aerobic glycolysis," and in 1970, biochemist Efraim Racker gave it the name we use today: the Warburg effect.

A Critical Distinction: Aerobic Glycolysis, Not Anaerobic Metabolism

A common misunderstanding — one that circulates widely in popular health media — is that cancer cells are "anaerobic" and that they "can't use oxygen." This is not what Warburg found, and it is not what modern science supports.

Cancer cells do use oxygen. They do have functioning mitochondria in most cases. What they also do, simultaneously, is run glycolysis at very high rates and convert large amounts of glucose to lactate — even though oxygen is right there. They are not anaerobic organisms trapped in an oxygen-rich environment. They are cells running two metabolic programs at once, with a strong preference for the glycolytic one.

This distinction matters because it determines how we interpret claims about "starving cancer of sugar" or "cutting off cancer's fuel supply." The biology is more nuanced than the popular framing suggests.

What Warburg Got Right

Warburg's core observation has been validated repeatedly over the past century and is now considered a near-universal feature of cancer. Several key confirmations:

It is a genuine hallmark of cancer. Douglas Hanahan and Robert Weinberg, in their influential 2011 update to the Hallmarks of Cancer framework, added "deregulating cellular energetics" as an emerging hallmark — a direct acknowledgment of the Warburg effect's centrality to cancer biology. Hanahan's 2022 update reinforced this position.

It is the basis for PET scanning. Positron emission tomography (PET) using fluorodeoxyglucose (FDG) — one of the most important diagnostic tools in modern oncology — works precisely because of the Warburg effect. FDG is a glucose analog that is taken up preferentially by cells with high glucose consumption. Cancer cells, because of their Warburg metabolism, light up on PET scans. Every PET scan performed in oncology is a clinical application of Warburg's 1924 observation.

Metabolic reprogramming is real and therapeutically relevant. Modern research has confirmed that cancer cells actively reprogram their metabolism. This reprogramming is driven by oncogenic signaling pathways — MYC, HIF-1α, PI3K/AKT/mTOR — and creates vulnerabilities that can potentially be exploited therapeutically.

What Warburg Got Wrong

Warburg made a bold claim that went beyond his experimental observations: he proposed that mitochondrial dysfunction was the primary cause of cancer. In his view, the metabolic shift to aerobic glycolysis was not a consequence of cancer but its root origin — that damaged mitochondria forced cells into a primitive fermentative metabolism, and this metabolic injury was the fundamental event that transformed normal cells into cancerous ones.

This hypothesis has not been supported by subsequent research. The modern consensus, supported by extensive molecular evidence, is that:

1. Mitochondria are not defective in most cancers. Cancer cells retain functional mitochondria and use them for both energy production and biosynthesis. The metabolic shift is not forced by broken mitochondria but chosen through active signaling.

2. The metabolic switch is a consequence, not a cause. Cancer arises from genetic and epigenetic alterations — mutations in oncogenes and tumor suppressors — that drive uncontrolled proliferation. The metabolic reprogramming is downstream of these changes, not upstream.

3. Aerobic glycolysis serves proliferation, not just energy. Perhaps the most important modern insight is why cancer cells choose the "inefficient" pathway. Glycolytic intermediates are diverted into biosynthetic pathways — nucleotide synthesis, amino acid production, lipid synthesis — that provide the raw materials for building new cells. For a rapidly dividing cell, having building blocks matters more than maximizing ATP yield. The Warburg effect is not a defect; it is an adaptation for proliferation.

Being honest about what Warburg got wrong is important because his causal hypothesis has been adopted — often without the necessary caveats — by proponents of metabolic cancer theories that overstate the therapeutic implications. The observation is solid; the causal hypothesis is not.

Why It Matters for Integrative Oncology

The Warburg effect creates the scientific context for several interventions that integrative oncology engages with:

Fasting and time-restricted eating. The rationale for fasting-mimicking diets and time-restricted eating in cancer care draws partly on the Warburg framework. If cancer cells are disproportionately dependent on glucose, then periods of reduced glucose availability might selectively stress cancer cells relative to normal cells. The de Groot DIRECT trial (2020), which tested a fasting-mimicking diet alongside neoadjuvant chemotherapy in breast cancer, and the Longo laboratory's preclinical work on differential stress resistance, both operate within this conceptual space. The clinical evidence remains early-stage, but the biological rationale connects directly to Warburg's observation.

Ketogenic diets. The strongest version of the metabolic therapy argument holds that severely restricting carbohydrates forces the body to produce ketone bodies, which normal cells can use but cancer cells (per the Warburg framework) supposedly cannot. The clinical reality is more complicated: cancer cells show considerable metabolic plasticity, and clinical trials of ketogenic diets in cancer have produced limited results. The most studied context is glioblastoma, where some signals exist but definitive evidence does not. The Warburg effect provides the theoretical rationale, but it does not guarantee the clinical outcome.

Metformin. The diabetes drug metformin activates AMPK (AMP-activated protein kinase), which among other effects opposes the mTOR signaling that drives much of the metabolic reprogramming in cancer cells. The epidemiologic observation that diabetic patients on metformin have lower cancer incidence led to extensive clinical investigation, including the MA.32 trial in breast cancer. Metformin's potential anti-cancer mechanisms intersect with the Warburg effect at the level of glucose and insulin signaling.

Exercise. Structured physical activity modifies the insulin/IGF-1 axis, reduces chronic inflammation, improves insulin sensitivity, and alters the metabolic environment in ways that may be unfavorable to cancer cells operating under Warburg metabolism. The 2025 CHALLENGE trial — which demonstrated that structured exercise after adjuvant chemotherapy for colon cancer reduced recurrence by 28% and mortality by 37% — represents the strongest clinical evidence that modifying the metabolic environment affects cancer outcomes.

The honest caveat. None of these interventions "starve cancer of sugar" in the simplistic way that popular media sometimes suggests. Cancer cells are metabolically flexible. Glucose restriction does not selectively kill cancer cells in most clinical contexts. The integrative oncology contribution is more nuanced: modifying the metabolic environment through exercise, dietary patterns, fasting timing, and metabolic agents may create conditions less favorable to cancer progression — not as primary treatment, but as adjuncts that work alongside surgery, radiation, chemotherapy, immunotherapy, and targeted therapy.

The Broader Lesson

The Warburg effect teaches a lesson that applies throughout integrative oncology: a genuine biological observation can coexist with exaggerated clinical claims. Warburg's observation is real, reproducible, and foundational. His causal hypothesis was wrong. The popular extrapolation — that sugar feeds cancer and therefore eliminating sugar cures cancer — is an oversimplification that the evidence does not support.

The responsible clinical position is neither to dismiss the Warburg effect as irrelevant nor to inflate it into a unified theory of cancer. It is to engage with the biology honestly, follow the clinical evidence where it leads, and communicate to patients what we know and what we do not.

That is the work of integrative oncology: sitting with complexity, resisting the temptation to oversimplify, and building clinical practice on what the evidence actually shows.

References

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.

Liberti, M. V., & Locasale, J. W. (2016). The Warburg effect: How does it benefit cancer cells? Trends in Biochemical Sciences, 41(3), 211–218.

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033.

Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.

Warburg, O., Posener, K., & Negelein, E. (1924). Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift, 152, 319–344.

Yoon Hang Kim MD MPH is a preventive medicine physician practicing integrative oncology in San Antonio, Texas. He is the author of Integrative Oncology for Clinicians, Researchers, and Empowered Patients (2026 Edition) - Manuscript in Preparation. For more information, visit www.directintegrativecare.com.